New Assay Predicts Leukemia Treatment Outcomes

Researchers developed a microfluidic tool to test how leukemia cells respond to various drug combinations.

Updated on Oct. 28, 2026 in Cancer

New Assay Predicts Leukemia Treatment Outcomes

Live Poll

Should hospitals adopt personalized lab-on-a-chip technology to speed up cancer treatment decisions?

Scientists have created the GradientScreen microfluidic assay to evaluate how childhood leukemia cells respond to drug combinations. The platform offers a new method to help predict efficacy and treatment outcomes for individual patients.

Why it matters

Standard leukemia treatments often lack tools to personalize dosages and predict effectiveness. This technology aims to address those gaps by measuring cancer cell survival rates to better inform patient care.

Researchers tested 17 leukemia cell and bone marrow samples using GradientScreen. These results correlated with patient residual disease levels, which is significant given that 15% of the pediatric population experiences leukemia relapse.

The players

Emory University

This Atlanta-based university is a primary research institution where the study was developed.

Georgia Tech

This research university collaborated as a primary institution on the microfluidic assay development.

Children's Healthcare of Atlanta

This organization operates the Aflac Cancer and Blood Disorders Center which facilitates local pediatric care.

The details

The GradientScreen platform uses microfluidic technology to expose leukemia cells to three-drug combinations within a single experiment. This approach allows researchers to measure how different ratios of drugs impact cancer cell survival rates.

October 27, 2026: Emory Health Sciences released the study findings.

Health Landscape

The research team plans to integrate this new microfluidic assay into the work being conducted at the Emory Lab for Innovative Assay Development. This moves the technology closer to clinical integration by establishing it within a permanent research infrastructure.

This development represents a step toward more personalized treatment plans that could eventually improve survival outcomes for pediatric leukemia patients. The technology aims to provide doctors with clearer data on how specific drug combinations will affect a patient's cancer cells.

The takeaway

This assay could provide clinicians with a more precise way to select effective drug combinations for children with leukemia. Future iterations of the technology are expected to expand testing capabilities to include adult patients and additional leukemia variants.